ISIS; Positive comments from Changewave investing newsletter

ISIS: Positive comments from Tobin Smith on his latest weekly update of Changewave Investing Newsletter.

Tobin Smith (a regular guest on bulls and bears on Fox) had the following comments on ISIS, following ALNY's deal with Roche. His target for ISIS remains at $20, which happens to be also Lehman's. I expect biotechs to outshine again towards ASH in early winter. If the atmosphere is right, I believe ISIS can trade above $20.

ISIS PHARMACEUTICALS (ISIS)

Isis Pharmaceuticals announced that it will receive $26.5 million from Alnylam Pharmaceuticals (ALNY) as its portion of the upfront fees and equity premium in the recently announced transaction between Roche Holding AG and Alnylam. In addition, Isis has the potential to receive milestone and royalty payments. This transaction underscores the value of Isis' innovation and the leadership role Isis has played in the f...